Delving into the Latest Updates on Abnova Taiwan Corp. with Synapse

Overview

Tags

Respiratory Diseases

Infectious Diseases

Prophylactic vaccine

saRNA vaccine

mRNA vaccine

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Infectious Diseases	4

Top 5 Drug Type	Count

Prophylactic vaccine	3
saRNA vaccine	2
mRNA vaccine	1
Monoclonal antibody	1

Top 5 Target	Count

SARS-CoV-2 S protein	2

Author: Masugi, Yohei ; Sonoda, Shinichiro ; Tsuda, Hitoshi ; Kato, Tomoyasu ; Kasamatsu, Takahiro ; Ida, Tomoaki ; Hashimoto, Yoshinori ; Ino, Yoshinori ; Honda, Kazufumi ; Itoh, Mai ; Akaike, Takaaki ; Yoshizawa, Hirotoshi ; Hishiki, Takako ; Kubo, Akiko ; Itai, Yuichiro ; Miura, Nami ; Yamamoto, Takehiro ; Shiota, Megumi ; Iwaisako, Keiko ; Hayakawa, Noriyo ; Yamamoto, Sohei ; Nagashima, Kengo ; Naito, Yoshiko ; Sakamoto, Michiie ; Huang, Wilber ; Uemoto, Shinji ; Yoshikawa, Tomoyuki ; Naya, Masayuki ; Nakamura, Seigo ; Matsuura, Tomomi ; Kabe, Yasuaki ; Chen, Wei-Yu ; Hiraoka, Nobuyoshi ; Takano, Masashi ; Koike, Daisuke ; Masui, Toshihiko ; Suematsu, Makoto ; Yoshida, Hiroshi ; Sakuma, Tomohiro ; Matsubara, Osamu

01 May 2021·Redox BiologyQ1 · BIOLOGY

On-tissue polysulfide visualization by surface-enhanced Raman spectroscopy benefits patients with ovarian cancer to predict post-operative chemosensitivity

Q1 · BIOLOGY

ArticleOA

Author: Masugi, Yohei ; Sonoda, Shinichiro ; Tsuda, Hitoshi ; Kasamatsu, Takahiro ; Kato, Tomoyasu ; Ida, Tomoaki ; Hashimoto, Yoshinori ; Ino, Yoshinori ; Honda, Kazufumi ; Itoh, Mai ; Akaike, Takaaki ; Yoshizawa, Hirotoshi ; Hishiki, Takako ; Kubo, Akiko ; Itai, Yuichiro ; Miura, Nami ; Iwaisako, Keiko ; Hayakawa, Noriyo ; Shiota, Megumi ; Yamamoto, Takehiro ; Yamamoto, Sohei ; Nagashima, Kengo ; Sakamoto, Michiie ; Naito, Yoshiko ; Huang, Wilber ; Uemoto, Shinji ; Yoshikawa, Tomoyuki ; Naya, Masayuki ; Nakamura, Seigo ; Matsuura, Tomomi ; Kabe, Yasuaki ; Chen, Wei-Yu ; Koike, Daisuke ; Hiraoka, Nobuyoshi ; Takano, Masashi ; Masui, Toshihiko ; Suematsu, Makoto ; Yoshida, Hiroshi ; Sakuma, Tomohiro ; Matsubara, Osamu

Chemosensitivity to cisplatin derivatives varies among individual patients with intractable malignancies including ovarian cancer, while how to unlock the resistance remain unknown. Ovarian cancer tissues were collected the debulking surgery in discovery- (n = 135) and validation- (n = 47) cohorts, to be analyzed with high-throughput automated immunohistochemistry which identified cystathionine γ-lyase (CSE) as an independent marker distinguishing non-responders from responders to post-operative platinum-based chemotherapy. We aimed to identify CSE-derived metabolites responsible for chemoresistant mechanisms: gold-nanoparticle (AuN)-based surface-enhanced Raman spectroscopy (SERS) was used to enhance electromagnetic fields which enabled to visualize multiple sulfur-containing metabolites through detecting scattering light from Au-S vibration two-dimensionally. Clear cell carcinoma (CCC) who turned out less sensitive to cisplatin than serous adenocarcinoma was classified into two groups by the intensities of SERS intensities at 480 cm^-1; patients with greater intensities displayed the shorter overall survival after the debulking surgery. The SERS signals were eliminated by topically applied monobromobimane that breaks sulfane-sulfur bonds of polysulfides to result in formation of sulfodibimane which was detected at 580 cm^-1, manifesting the presence of polysulfides in cancer tissues. CCC-derived cancer cell lines in culture were resistant against cisplatin, but treatment with ambroxol, an expectorant degrading polysulfides, renders the cells CDDP-susceptible. Co-administration of ambroxol with cisplatin significantly suppressed growth of cancer xenografts in nude mice. Furthermore, polysulfides, but neither glutathione nor hypotaurine, attenuated cisplatin-induced disturbance of DNA supercoiling. Polysulfide detection by on-tissue SERS thus enables to predict prognosis of cisplatin-based chemotherapy. The current findings suggest polysulfide degradation as a stratagem unlocking cisplatin chemoresistance.

04 Dec 2020·Neuro-Oncology

DIPG-60. PILOT STUDY OF CIRCULATING TUMOR CELLS IN PEDIATRIC HIGH GRADE BRAIN TUMORS

Author: Wilber Huang ; Soumen Khatua ; Wafik Zaky ; Ssu-Hsien Chen ; Shulin Li ; Jonathan Gill ; Izhar Batth ; Najat Daw ; Aish Albert

AbstractBACKGROUNDDespite its increasing use, circulating tumor cells (CTCs) have not been studied in pediatric brain tumors.METHODSCell surface vimentin (CSV) is a marker for CTC detection. We developed an automated CSV-based CTC capture method for pediatric brain tumor using the Abnova Cytoquest platform. PBMCs isolated from blood samples from 52 brain tumor patients were processed to isolate CSV+ CTCs. Captured cells were then stained for CSV and CD45 and scanned to determine the number of CTCs. DIPG samples were additionally examined for H3K27M expression on CSV+ cells. Long term cancer survivors were used as a control cohort.RESULTS86.4% of all the samples exhibited between 1–13 CSV+ CTCs, with a median of 2 CSV+ CTCs per sample. Using a value of ≥ 1 CTC as a positive result, the sensitivity and specificity of this test was 83.05% and 60.0% respectively. 19 DIPG samples were analyzed and 70% (13 samples) were positive for 1–5 CTCs. Five of these 7 positive CSV+ CTCs DIPG samples were also positive for H3K27M mutations by immunohistochemistry (71%). Mean survival in days for the CTC positive and negative DIPG samples were 114 and 211 days, respectively (p= 0.13).CONCLUSIONThis is the first study of CTCs in pediatric CNS tumors using an automated approach. Patients with brain tumors can exhibit CSV+ CTCs within peripheral blood. The use of specific molecular markers such as H3K27M can improve the diagnostic capability of liquid biopsies and may enable future disease assessment for personalized therapy.

100 Deals associated with Abnova Taiwan Corp.

Login to view more data

100 Translational Medicine associated with Abnova Taiwan Corp.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 30 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

4

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

COVID-19 self-amplifying mRNA vaccine (Abnova) ( SARS-CoV-2 S protein )	COVID-19 More	Preclinical
7-F-7 ( SARS-CoV-2 S protein )	COVID-19 More	Preclinical
COVID-19 SAM vaccine(Abnova Taiwan Corp.)	COVID-19 More	Preclinical
COVID-19 SAM vaccine (Abnova Corporation)	COVID-19 More	Preclinical